INTRODUCTION
Alkylating agents are of major importance in the treatment of malignant solid tumours in childhood. The efficacy and toxicity of one such agent, cyclophosphamide (an oxazophorine) have been widely reported. Ifosfamide, another drug of the oxazophorine class, has been shown to be active against a wide range of human malignancies in both adults and children. There is evidence to suggest that Ifosfamide and Cyclophosphamide have significant differences in their modes of action, spectrum of activity and toxicity (1) . Phase II trials using ifosfamide began in the early 1970's but its use was restricted until recently by the major dose-limiting sideeffect of urothelial toxicity. Recent studies have shown that the thiol compound Sodium 2 mercaptoethane sulphonate (MESNA) protects the urothelium from the toxic effects associated with high dose oxazophorine therapy, probably by combining with and inactivating their toxic metabolites, particularly acrolein.
Since November 1983, Ifosfamide has been incorporated in some of our first-line chemotherapeutic regimens in the treatment of solid malignancies of childhood. This paper reports the toxicity experienced in the first thirty children treated by us with Ifosfamide (92 courses) when used bottT'as a single agent and in combination with the epipodophyllotoxin VP16(213) ( Table 1 ). The response rates to these regimens will be reported elsewhere. 
